Clinical Trials Browser

Phase 2 × Vipoma × Octreotide × Clear all

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Phase 2 Completed

150 enrolled 12 charts

Vipoma

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Phase 2 Withdrawn

Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00466856 2012-05-18

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Phase 2 Terminated

10 enrolled

EndocrineHead & Neck

Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Neoplasms, Pheochromocytoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Clinical Trials

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors